Keywords
Vital Signs ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

716 Search results.

CDASH Vital Signs

- 6/20/18 - 1 form, 2 itemgroups, 14 items, 2 languages
Itemgroups: General information, Vital Sign
modified from http://www.cdisc.org

EHR4CR Complete Data Inventory - EHR4CR Data Inventory

- 2/10/17 - 1 form, 13 itemgroups, 122 items, 1 language
Itemgroups: Demographics, Diagnoses and Procedures, Vital Signs, Laboratory, Generic Laboratory Data, Medication, Adverse Events, Medical History, Clinical Findings, ECG, Patient Reported Outcome, Substance Use, Study Participation Status
Compilation of Feasibility, Patient Identification & Recruitment and Clinical Trial Execution data inventories. https://www.ncbi.nlm.nih.gov/pubmed/24410735 https://www.ncbi.nlm.nih.gov/pubmed/25991199 https://www.ncbi.nlm.nih.gov/pubmed/27875988

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 4 - Vital Signs; Electronically Transferred Lab Data; Liver event assessment; PK Tissue Sample; 12-Lead ECG

- 2/26/20 - 1 form, 8 itemgroups, 30 items, 1 language
Itemgroups: Administrative, Vital Signs, First sitting BP reading, Second sitting BP reading , Electronically Transferred Lab Data , Liver event assessment, PK Tissue Sample, 12-Lead ECG
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Vital signs

- 2/24/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Administrative Data, Vital signs
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the vital signs form. It has to be filled in for screening, V2b, V3, V4, V5, follow-up and if required for logs/ repeats.

GSK1034702 after Repeat Doses in Healthy Subjects; NCT00950586 - V4

- 2/23/20 - 1 form, 20 itemgroups, 672 items, 1 language
Itemgroups: Date of visit, Experimental drug, Therapeutic procedure, Confirmation, Blood Pressure Monitoring, Ambulatory, Cognitive functions, Tests, Vital signs, Holter Electrocardiography, Abnormality, Telemetry, Telemetry, Abnormality, Laboratory Procedures, Pulmonary function tests, Pharmacokinetic aspects, Blood, Pharmacokinetic aspects, Urine, Saliva specimen, Vital signs, Vital signs, Vital signs, Vital signs, Vital signs, Vital signs
Study ID: 110792 Clinical Study ID: 110792 Study Title: A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950586 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Dextromethorphan, Placebo Trade Name: N/A Study Indication: Cognitive Disorders

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Unscheduled - Vital Signs; Electronically Transferred Lab Data; Liver event assessment; ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; External Ocular Exam; Eye Lid and Lash Exam

- 2/17/20 - 1 form, 15 itemgroups, 68 items, 1 language
Itemgroups: Administrative, Vital Signs, First sitting BP reading, Second sitting BP reading , Electronically Transferred Lab Data , Liver event assessment, ETDRS Refraction , ETDRS Visual Acuity , Intraocular Pressure Exam , External Ocular Exam , Pupil Exam - Right Eye , Pupil Exam - Left Eye , Motility Exam , Confrontation Visual Field , Eye Lid and Lash Exam
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Day 1 - Vital Signs; Electronically Transferred Lab Data; Liver event assessment; ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; External Ocular Exam; Eye Lid and Lash Exam; Iris Color

- 2/5/20 - 1 form, 16 itemgroups, 70 items, 1 language
Itemgroups: Administrative, Vital Signs, First sitting BP reading, Second sitting BP reading , Electronically Transferred Lab Data , Liver event assessment, ETDRS Refraction , ETDRS Visual Acuity , Intraocular Pressure Exam , External Ocular Exam , Pupil Exam - Right Eye , Pupil Exam - Left Eye , Motility Exam , Confrontation Visual Field , Eye Lid and Lash Exam , Iris Color
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

GSK1034702 after Repeat Doses in Healthy Subjects; NCT00950586 - Logs and Repeats

- 2/1/20 - 1 form, 16 itemgroups, 156 items, 1 language
Itemgroups: Date of visit, Assessment Date, Adverse Event; Concomitant Agent; Evaluation, Repeat, Liver, Adverse Event, Non-serious Adverse Event, Serious Adverse Event, Concomitant Agent, Laboratory Procedures, Vital signs, Pharmacokinetic aspect, Blood, Repeat, Pulmonary function tests, Repeat, Holter Electrocardiography, Repeat, Holter Electrocardiography, Abnormality, Repeat, Telemetry, Repeat, Telemetry, Abnormality, Repeat, 12 lead ECG, Abnormality, Repeat, 12 lead ECG
Study ID: 110792 Clinical Study ID: 110792 Study Title: A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950586 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Dextromethorphan, Placebo Trade Name: N/A Study Indication: Cognitive Disorders

GSK1034702 after Repeat Doses in Healthy Subjects; NCT00950586 - V1

- 2/1/20 - 1 form, 7 itemgroups, 21 items, 1 language
Itemgroups: Date of visit, Cytochrome P450 2D6 Inhibitors [MoA], Status, Blood Pressure Monitoring, Ambulatory, Holter Electrocardiography, Holter Electrocardiography, Abnormality, Laboratory Procedures, Vital signs
Study ID: 110792 Clinical Study ID: 110792 Study Title: A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950586 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Dextromethorphan, Placebo Trade Name: N/A Study Indication: Cognitive Disorders

GSK1034702 after Repeat Doses in Healthy Subjects; NCT00950586 - V2

- 2/1/20 - 1 form, 14 itemgroups, 257 items, 1 language
Itemgroups: Date of visit, Experimental drug, Dosage, Therapeutic procedure, Confirmation, Holter Electrocardiography, Holter Electrocardiography, Abnormality, Telemetry, Telemetry, Abnormality, Laboratory Procedures, Laboratory Procedures, Pulmonary function tests, Pharmacokinetic aspects, Blood, Pharmacokinetic aspects, Urine, Saliva specimen, Vital signs
Study ID: 110792 Clinical Study ID: 110792 Study Title: A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950586 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Dextromethorphan, Placebo Trade Name: N/A Study Indication: Cognitive Disorders

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Screen - Medical / surgical procedures; Risk Factors; Vital Signs; History of Tobacco Use; Alcohol intake

- 1/10/20 - 1 form, 10 itemgroups, 31 items, 1 language
Itemgroups: Medical/ surgical procedures - Right Eye, Medical/ surgical procedures - Left Eye , Other ocular surgeries and procedures, Risk Factors, Vital Signs, First sitting BP reading, Second sitting BP reading , Third sitting BP reading , History of Tobacco Use, Alcohol intake
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Ropinirole prolonged release (PR) as adjunctive treatment to L-Dopa in patients with advanced Parkinson's disease (NCT01494532) - Visit 1; Visit 2; Visit 3; Visit 4; Visit 5; Visit 6; Visit 7; Visit 8; Visit Maintenance 1 +2; Early Withdrawal; Follow up; Optional Visit; Unscheduled - PR/Conmeds; SOOS; Vitals

- 1/9/20 - 1 form, 8 itemgroups, 54 items, 1 language
Itemgroups: Administrative, Prior/ Current Concomitant Medications, Prior/ current non-drug therapies, Non-drug therapies, Sudden Onset of Sleep Questionnaire, Vital Signs - Semi supine , Vital Signs - Standing , Physical Exam
Study ID: 111569 Clinical Study ID: 111569 Study Title: A fixed dose, dose-response study for ropinirole prolonged release (PR) as adjunctive treatment to L-Dopa in patients with advanced Parkinson's disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01494532 Sponsor: GlaxoSmithKline Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Ropinirole, placebo Study Indication: Parkinson's Disease